Active Ingredient History
Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly. It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy. It is delivered as a powder that is mixed with water and injected under the skin. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acromegaly ()
Biological Availability (Phase 1)
Breast Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 1)
Diabetes Mellitus (Phase 2)
Fibrous Dysplasia, Polyostotic (Phase 3)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 4)
Hypertrophy, Left Ventricular (Phase 4)
Insulin Resistance (Phase 2)
Lipodystrophy (Phase 2)
Lung Neoplasms (Phase 1)
Metabolic Syndrome (Phase 2)
Mutation (Phase 2)
Obesity (Phase 4)
Pituitary Diseases (Phase 3)
Prostatic Neoplasms (Phase 1)
Quality of Life (Phase 4)
Sarcoma (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
